Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Antibiotic therapy for small intestinal bacterial overgrowth

This month's issue of the Alimentary Pharmacology & Therapeutics reviews antibiotic therapy for small intestinal bacterial overgrowth.

News image

Small intestinal bacterial overgrowth is an under-recognised diagnosis with important clinical implications when untreated.

However, the optimal treatment regimen remains unclear.

Dr Sewell and colleagues from California, USA performed a systematic review and meta-analysis comparing the clinical effectiveness of antibiotic therapies in the treatment of symptomatic patients with documented small intestinal bacterial overgrowth.

The team searched 4 databases to identify clinical trials comparing effectiveness of different antibiotics, different doses of the same antibiotic, and antibiotics compared with placebo.

Data were independently extracted according to predetermined inclusion and exclusion criteria.

Rifaximin was the most commonly studied antibiotic with overall breath test normalization rate of 50%
Alimentary Pharmacology & Therapeutics

Study quality was independently assessed.

The researchers' primary outcome was normalization of post-treatment breath testing.

The secondary outcome was post-treatment clinical response.

Of 1356 articles identified, 10 met inclusion criteria.

The research team found that rifaximin was the most commonly studied antibiotic with overall breath test normalization rate of 50%.

The team observed that antibiotic efficacy varied by antibiotic regimen and dose.

Antibiotics were more effective than placebo, with a combined breath test normalization rate of 51% for antibiotics compared with 10% for placebo.

Meta-analysis of 4 studies favored antibiotics over placebo for breath test normalization with an odds ratio of 2.55.

The team heterogeneously evaluated clinical response among 6 studies, but tended to correlate with breath test normalization.

Dr Sewell's team concluded, "Antibiotics appear to be more effective than placebo for breath test normalization in patients with symptoms attributable to small intestinal bacterial overgrowth, and breath test normalisation may correlate with clinical response."

"Studies were limited by modest quality, small sample size and heterogeneous design."

"Additional higher quality clinical trials of small intestinal bacterial overgrowth therapy are warranted."

Aliment Pharmacol Ther 2013: 38(8): 925934
02 October 2013

Go to top of page Email this page Email this page to a colleague

 26 January 2015

Advanced search
 26 January 2015 
Breath analysis for IBD
 26 January 2015 
Fecal microbiota transplantation
 26 January 2015 
Antidepressants and GERD
 23 January 2015 
Liver transplant outcomes
 23 January 2015 
Breath analysis in IBD
 23 January 2015 
Fecal microbiota transplantation
 22 January 2015 
NASH and lipid improvements
 22 January 2015 
NAFLD and NASH with psoriasis
 22 January 2015 
Predicting outcomes in HCV-related advanced liver disease
 21 January 2015 
Colon capsule versus CT colonography
 21 January 2015 
Barrett's esophagus screening in the community
 21 January 2015 
Portal vein obstruction
 20 January 2015 
Modulating mucosal damage in Crohn's
 20 January 2015 
Food intolerance
 20 January 2015 
Novel techniques for Barrett's screening
 19 January 2015 
Treatment of fecal incontinence
 19 January 2015 
Hepatic cyst infection
 19 January 2015 
Risk of IBS among relatives
 16 January 2015 
Fecal incontinence
 16 January 2015 
Colorectal cancer screening uptake
 16 January 2015 
NAFLD and NASH in patients with psoriasis
 15 January 2015 
Coffee intake and liver disease
 15 January 2015 
NAFLD in primary care practice
 15 January 2015 
Management of univestigated dyspepsia
 14 January 2015 
Missed colorectal cancers after colonoscopy with polypectomy
 14 January 2015 
Inflixmab response in Crohn's
 14 January 2015 
Statins and liver injury in chronic liver disease
 13 January 2015 
Cytomegalovirus in IBD
 13 January 2015 
Helicobacter-negative gastritis
 13 January 2015 
Hep B vaccine in IBD
 12 January 2015 
Survival in Hep B virus-related hepatocellular carcinoma
 12 January 2015 
Relapse of Crohn's disease after surgery
 12 January 2015 
Late liver metastases of colorectal cancer
 09 January 2015 
Fecal microbiota transplantation for refractory Crohn's
 09 January 2015 
Hypercoagulability after liver resection
 09 January 2015 
Naps and gastroesophageal reflux vs nocturnal sleep
 08 January 2015 
Post-infectious functional dyspepsia
 08 January 2015 
Diagnosis of liver iron overload
 08 January 2015 
Digestive tract damage in Crohn's disease
 07 January 2015 
Early-onset colorectal cancer
 07 January 2015 
SSRIs for noncardiac chest pain
 07 January 2015 
SSRIs and upper GI bleeds
 06 January 2015 
Detection of inflammation in Crohn's
 06 January 2015 
Leptin and early-onset extreme obesity
 06 January 2015 
Goals of IBD treatment
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives
 18 December 2014 
Vitamin D and sustained virologic response in HCV
 18 December 2014 
Factor for treatment in IBS
 18 December 2014 
Assessment of Crohn's disease activity
 17 December 2014 
Remission from hepatic encephalopathy with rifaximin
 17 December 2014 
Colonic adenoma recurrence after endoscopic resection
 17 December 2014 
Non-invasive measures of fatty liver
 16 December 2014 
Diagnostic tool for dysplasia in Barrett's
 16 December 2014 
Screening esophagus during routine US
 16 December 2014 
Therapeutic targets in IBD
 15 December 2014 
Food allergy and food intolerances
 15 December 2014 
Esophageal adenocarcinoma and Barrett's
 15 December 2014 
Outcomes of mildly abnormal liver function tests

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us